Instrumentation And Validation

Method Validation Parameters

Before a new method reports patient results, the laboratory performs method validation to document performance. Under CLIA '88, the depth of validation depends on test complexity, and laboratories must verify or establish each parameter:

Accuracy vs precision is a perennial trap: accuracy is closeness to the true value; precision is reproducibility (low CV). A method can be precise but inaccurate. Accuracy is monitored long-term through proficiency testing (PT) — blinded samples sent by an approved provider; CLIA requires PT for regulated analytes, and unsatisfactory performance can suspend testing for that analyte.

CLIA complexity tiers determine personnel and validation requirements:

• Waived — simple, low-risk (e.g., dipstick urinalysis, fingerstick glucose); CLIA Certificate of Waiver.
• Moderate complexity — most automated chemistry/hematology.
• High complexity — manual differentials, molecular testing, blood bank workups.

Nonwaived tests require competency assessment of testing personnel: at six months and then annually, using the six CLIA elements (direct observation, monitoring recording/reporting, review of QC/PT, instrument maintenance, problem solving, and unknown-sample testing).

Calibration, Linearity, And Failure Modes

Calibration assigns the response curve using calibrators of known concentration; calibration verification confirms the instrument still reads accurately across the analytical measurement range (AMR) and is performed at least every six months, after major maintenance, or when QC trends fail. A result above the linearity limit must be diluted and reassayed, then multiplied by the dilution factor — reporting an off-scale value as the upper limit is incorrect.

Linearity study example: a tech assays five glucose linearity standards (0, 100, 200, 400, 800 mg/dL). If the plot is straight through 400 but flattens at 800, the upper reportable limit is 400 mg/dL; specimens above 400 must be diluted.

Recognize instrument failure modes and interferences, which are common procedural distractors:

• Carryover — residual sample/reagent contaminating the next test; suspected when a very high specimen is followed by a falsely elevated low one.
• Hemolysis — falsely increases potassium, LDH, AST, phosphorus (intracellular release).
• Lipemia — causes turbidity interfering with photometric reads and pseudohyponatremia by indirect ISE.
• Icterus (bilirubin) — spectral interference at some wavelengths.
• Deteriorating reagent or aging lamp/electrode — produces a QC trend (gradual drift), tying validation back to Westgard interpretation.

Worked example: QC has slowly trended upward 0.2SD per day for two weeks while reagent and calibration are unchanged. A failing photometer lamp or deteriorating reagent is the likely root cause; the corrective action is to replace the lamp/reagent and recalibrate, then re-verify linearity before resuming patient testing.

Establishing Performance: Comparison, Precision, And Reference Intervals

Validating a quantitative method follows a defined experimental sequence the exam expects you to recognize:

• Method comparison — run 40+ patient samples on the new method and the reference/comparative method, then perform regression analysis. The slope reveals proportional (multiplicative) error, the y-intercept reveals constant (additive) error, and the correlation coefficient (r) describes agreement (r ≥ 0.975 is typically desired). A slope of 1.0 and intercept of 0 indicate no systematic bias.
• Precision study — replicate a control within-run and between-run (e.g., 20 days), reporting the CV at medical-decision concentrations.
• Recovery and interference — spike known analyte and add hemolysate/lipid/bilirubin to quantify bias.
• Reference interval verification — assay ~20 samples from healthy individuals; if ≤2 fall outside the manufacturer's interval, it is verified for the population.

Worked example: a new ALT method's regression versus the old gives slope 1.0 but y-intercept = +8 U/L. This is constant error (a fixed offset across all concentrations), pointing to a blank or baseline problem, not a calibration-slope issue.

CLIA Complexity, Calibration Verification, And Interference Detection

Linearity material and calibration verification confirm the analytical measurement range (AMR); CLIA requires verification at least every six months, after reagent-lot changes that affect calibration, after major maintenance, and when QC indicates drift. The clinically reportable range (CRR) extends the AMR using validated dilutions — results above the AMR are diluted, reassayed, and multiplied by the dilution factor.

Know how interferences present so you can pick the right corrective action:

Maintenance discipline prevents many failures: daily probe/wash checks, scheduled lamp replacement, temperature monitoring of incubation chambers and refrigerators, and water-quality (Type I reagent-grade) verification. When a stem describes an instrument that recently passed QC but now produces a gradual one-directional drift with unchanged calibration and reagent, the best-supported root cause is a deteriorating component (lamp, electrode, or pump) — and the validated response is to service the component, recalibrate, and document before resuming patient reporting.

As always on this exam, anchor the answer to the specific failure mode the stem describes rather than to the most technical-sounding option.